According to a recent LinkedIn post from CurifyLabs, compounding pharmacy owner Tyler Young described his experience using the company’s 3D printer, citing faster and more efficient production, accurate output, and individual weighing of troches and suppositories. The post also indicates an upcoming update intended to enable weighing of each capsule.
The post suggests these controls could support more consistent formulations and a cleaner finished product for patients, although it provides no measured performance data or independent validation. For investors, the update points to product development aimed at addressing operational and quality-control needs among compounding pharmacies.
Broader adoption could strengthen CurifyLabs’ position in pharmacy automation if the printer demonstrates repeatable efficiency and accuracy across customers. However, the post offers no information on sales volume, pricing, regulatory status, adoption pipeline, or expected financial contribution.
Interest from independent and rural pharmacies may indicate a target market for CurifyLabs’ technology, but customer interest alone does not establish commercial traction. Converting that interest into recurring revenue will likely depend on implementation requirements, customer support, and further evidence of operational benefits.

